Alison Dziarmaga

Oncology

Interview at ASCO 2025 with Alison Dziarmaga

Following science to fruition, putting patients first: An AS...

At ASCO25, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial. Alison Dziarmaga discussed the data with pharmaphorum.

News

Sentynl gets first FDA approval for rare disease Menkes

Children with a devastating, rare disorder of copper metabolism, called Menkes disease, now have an FDA-approved treatment for the first time.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks